Di Yi Cai Jing·2026-01-26 11:21Core Viewpoint - The A-share biopharmaceutical sector experienced a significant rally, with multiple companies reaching the daily limit up due to the outbreak of the Nipah virus in India, which has a high mortality rate and no specific vaccine or effective treatment available [1] Group 1: Market Reaction - A-share biopharmaceutical stocks surged across the board, with companies like Mike Biologics, Cap Biologics, Zhijiang Biologics, Hualan Vaccine, and Jindike hitting the 20% daily limit up [1] - The biopharmaceutical ETF index saw a notable increase of approximately 2% in the afternoon trading session [1] Group 2: Nipah Virus Outbreak - The Nipah virus outbreak in West Bengal, India, has a mortality rate that can reach up to 75% and is transmissible between humans [1] - The Thai Civil Aviation Authority announced comprehensive screening for flights from the affected region starting from the 26th [1] - In China, the newly revised "Law of the People's Republic of China on Frontier Health and Quarantine" has included the Nipah virus in its monitoring directory [1] Group 3: Company Responses - Companies like Shuoshi Biologics and Cap Biologics have stated that they provide Nipah virus nucleic acid testing kits to assist in epidemic monitoring and port control [1] - Zhijiang Biologics mentioned that it has relevant testing products primarily sold to the Middle East, with no current orders from India [1] - The sales volume of related products is reported to be at a normal level, with a minor contribution to overall revenue [1]